• Help people with EB

    Your support of DEBRA International or a national EB group enables us to provide the best quality of life for families and individuals affected by EB.

Donation Account: IBAN AT65 6000 0005 1004 5254, BIC BAWAATWW, DEBRA International, Am Heumarkt 27/1, 1030 Vienna

donate now

DEBRA International is now inviting research proposals across DEBRA's four priority research areas.

Please note that research proposals to the Spring 2017 ‘All-Priorities’ Research Call, including the re-submission of previously unsuccessful proposals may only be made using the online grant-application system – see the ‘Submission’ section below.

PLEASE DO NOT USE OLD-STYLE WORD OR PDF APPLICATION FORMS AS IT WILL NOT BE POSSIBLE TO ACCEPT SUCH PROPOSALS FOR CONSIDERATION

Only extension requests for current research grants may be submitted offline. You will find the necessary document in the Grant Extension box on the left.

Application process                    Submission          Review process   

Current research priorities         Criteria                 Co-funding


Application process

This is a one-stage process of application.

Submission

· The submission deadline for online applications is 19th April 2017.
· Research proposals must be submitted via our online system
  https://grants.debra-international.org/
·
If you are experiencing any technical problems or your query is not answered in the information
  provided in the system, please contact 
cornelia.schrauf@debra-austria.org.
· Please read the Terms and Conditions before completing an application form.
· If you are applying for an extension (one-year maximum) to an existing DEBRA research grant,
  please complete the application form for grant extensions. You will find the necessary document
  in the Grant Extension box on the left.

Review process

·
Research Proposals will be reviewed by external reviewers and members of DEBRA
  International's 
Medical & Scientific Advisory Panel (MSAP) on 24th September 2017.
  Recommendations for funding made by MSAP at a grant review meeting will then be considered
  by DEBRA's Boards of Trustees.
· Subject to funding availability, allocation of funds will recognise an equal prioritisation of
  the 
research areas, while adhering to the core principle of funding the best research, identified
  by MSAP as meeting the criteria of scientific quality, feasibility and patient benefit.
· The final funding decision will be at the discretion of DEBRA International. It is anticipated that
  funding decisions will be made no later than November 2017.

Current research priorities

·
Improve our understanding of the biology and genetics of all forms of EB, as better
  understanding can lead to new approaches to diagnose and treat EB
· Work towards the development of therapies (including possible gene-therapies, cell-
  therapies, drug therapies or protein therapies)
· Understand the nature of wound healing and the development of skin cancer in EB, and seek
  to develop better treatments and prevention strategies
· Support clinical care research to improve the management of EB through symptom relief

Criteria

·
One of the defined priority research areas
· Between 6 months and 3 years duration
· It is expected that funding requests would not exceed €90K per annum; however, funding in
  excess of these amounts may be allowed if considered by DEBRA to be adequately justified in
  the grant application, and subject to funding availability
· Currency may be USD, EUR or GBP; contracts will be issued in USD, EUR or GBP for a binding
  amount

Co-Funding

·
DEBRA International welcomes proposals for co-funding with other organisations, including
  government, academia, industry or other charities.
· DEBRA will not, however, fund generic technology development costs not closely related to a
  specific EB therapeutic approach.
· If in doubt about whether your application would be eligible, please contact Dr Clare Robinson,
  DEBRA International Head of Research 
clare.robinson@debra-international.org, before
  submitting a full application.